Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Trading 11-22 11:27:35 EST

12.02

+0.15

+1.26%

High12.07	Low11.84	Vol22.66K
Open11.89	D1 Closing11.87	Amplitude1.91%
Mkt Cap598.22M	Tradable Cap325.24M	Total Shares49.77M
T/O271.90K	T/O Rate0.08%	Tradable Shares27.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":12.02,"timestamp":1732292820773,"preClose":11.87,"halted":0,"volume":22655,"delay":0,"floatShares":27058429,"shares":49768669,"eps":-3.325675,"marketStatus":"Trading","change":0.15,"latestTime":"11-22 11:27:35 EST","open":11.89,"high":12.07,"low":11.843,"amount":271896.15738,"amplitude":0.019124,"askPrice":12.05,"askSize":262,"bidPrice":11.96,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.325675,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732309200000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":11.87,"preHourTrading":{"tag":"盘前","latestPrice":11.87,"preClose":11.87,"latestTime":"09:12 EST","volume":1,"amount":11.87,"timestamp":1732284734755},"postHourTrading":{"tag":"盘后","latestPrice":12.46,"preClose":11.87,"latestTime":"17:56 EST","volume":2135,"amount":25475.2,"timestamp":1732229805070},"volumeRatio":0.369002,"impliedVol":0.3886,"impliedVolPercentile":0.2024},"requestUrl":"/m/hq/s/MLYS/tweets","defaultTab":"tweets","newsList":[{"id":"2482808467","title":"Q3 2024 Mineralys Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2482808467","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482808467?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:12","pubTimestamp":1731424374,"startTime":"0","endTime":"0","summary":"Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. Adam Levy; Chief Financial Officer, Company Secretary; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer; Mineralys Therapeutics Inc. Thank you, Dan. Good afternoon, everyone, and welcome to our third-quarter 2024 financial-results and corporate update conference call. I'm joined today by Adam Levy, our Chief Financial Officer; and Dr. David Rodman, our Chief Medical Officer. I'll begin with an overview of the business, our clinical programs and recent milestones. Then Adam will review our third quarter financial results before we open up the call for your questions. I want to kick things off with a recap of the progress the Mineralys team has made these past several months, advancing our pivotal clinical development of lorundrostat in hypertension and then discuss the upcoming milestones we anticipate throughout the first half of 2025. We recently completed enrollment in our pivotal Advance-HTN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-mineralys-therapeutics-inc-151254278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","MLYS"],"gpt_icon":0},{"id":"2482088221","title":"Mineralys Therapeutics, Inc. (MLYS) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088221?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:15","pubTimestamp":1731420957,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report) today and set a price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mineralys-therapeutics-inc-mlys-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mineralys-therapeutics-inc-mlys-gets-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","MLYS","SF","BK4139"],"gpt_icon":0},{"id":"2482714569","title":"Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482714569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482714569?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:43","pubTimestamp":1731382994,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryMineralys Therapeutics Inc MLYS.OQ reported a quarterly adjusted loss of $1.13 per share for the quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ04L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS"],"gpt_icon":0},{"id":"2482761328","title":"Mineralys Therapeutics Q3 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2482761328","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482761328?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:56","pubTimestamp":1731362200,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  reported a Q3 net loss late Monday of $1.13 per diluted share, widening from $0.57 a year earlier.Analysts polled by Capital IQ expected a loss of $0.83.Cash, cash equivalents and investments as of Sept. 30 were $263.6 million, up from $239 million as of Dec. 31, 2023.Mineralys said it expects current cash, cash equivalents and investments to fund clinical trials and corporate operations into 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","MLYS"],"gpt_icon":0},{"id":"2482765525","title":"Mineralys Therapeutics Q3 2024 GAAP EPS $(1.13) Misses $(0.83) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482765525","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482765525?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:07","pubTimestamp":1731359231,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.83) by 36.14 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41887840/mineralys-therapeutics-q3-2024-gaap-eps-1-13-misses-0-83-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","LENZ"],"gpt_icon":0},{"id":"2482765864","title":"Mineralys Therapeutics Q3 Operating Expenses USD 60.106 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2482765864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482765864?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nPLXC88226:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2482420129","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2482420129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482420129?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:00","pubTimestamp":1731322800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Angi Inc Class A                                3Q       .00       AMC. ·Global Ship Lease                                3Q      2.41   8:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","IAC","AMTX","CRVO","KEP","DDI","GAUZ","IKT","ATER","NRGV","CNNE","ICL","ARMK","ASRT","FLNG","CLRB","RVPH","LAZR","GATO","XGN","OBIO","CNTA","EARN","ABSI","DAVE","XP","AZN","DHX","GENI","SGMT","INTS","EQ","MLYS","NOTE","FIHL","TWKS","CRDL","DHT","DAVA","TSVT","CHGG","CCLD","ABOS","BLFS","CYTH","FBRX","AXSM","FTCI","AVTE","CAE"],"gpt_icon":0},{"id":"2482046153","title":"Mineralys Therapeutics Inc  expected to post a loss of 83 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482046153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482046153?lang=en_us&edition=fundamental","pubTime":"2024-11-09 08:37","pubTimestamp":1731112658,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc  expected to post a loss of83cents a share - Earnings Preview Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to show no change in quarterly revenue when it reports  r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241109:nL8N3MG037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS"],"gpt_icon":0},{"id":"2481385651","title":"Mineralys Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2481385651","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481385651?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:05","pubTimestamp":1730840700,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Nov.  05, 2024  (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2975209/0/en/Mineralys-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","MLYS"],"gpt_icon":1},{"id":"2481761145","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2481761145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481761145?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:00","pubTimestamp":1730804400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·AG Mtge Invest.                                 3Q       .21    6:30 AM. ·American Fncl Gp                                 3Q      2.47    5:00 PM. ·Apollo Global Mgmnt                              3Q      1.73    6:30 AM. ·Bain Cap Spec Fin                               3Q       .50        AMC. ·Ballard Power Sys                               3Q      (.13)   8:30 AM. ·Broadridge Fncl Sltns                             1Q       .97    7:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTLT","NMRK","MGNX","MLYS","GGB","CGBD","MRC","AFG","RACE","ERO","DD","MRNS","OGE","FHTX","INZY","NVEI","BLDP","INNV","CMI","NOG","MRCY","OLMA","AGCO","BRKR","CRC","GBTG","BBAI","AGEN","RNA","APO","EVRI","LUMN","CTKB","CRBP","GMED","FORR","IMOS","BLDR","FTS","LDI","ARCH","EXK","GLDD","JKHY","MITT","LPX","AIP","HSIC","SWIM"],"gpt_icon":1},{"id":"2481554202","title":"Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481554202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481554202?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:05","pubTimestamp":1730754300,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Nov. 04, 2024  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease  and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024.A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.Media RelationsTom WeibleElixir Health Public RelationsPhone:  515-707-9678Email: tweible@elixirhealthpr.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ifkc06INacfJPqh.gDBfdQ--~B/aD0zMTY7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/90226c9fda7ac1f347f758bb5fb98743"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mineralys-therapeutics-announce-third-quarter-210500374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MLYS","BK4139","HST","BK4181","BK4218","BK4588","BK4585","LENZ"],"gpt_icon":1},{"id":"2479057207","title":"BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2479057207","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479057207?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:11","pubTimestamp":1730293916,"startTime":"0","endTime":"0","summary":"Oct 30  - Mineralys Therapeutics Inc   :   * MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF SCHEDULE IN LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION   * MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM LAUNCH-HTN TRIAL EXPECTED MID FIRST HALF OF 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MLYS","BK4139"],"gpt_icon":0},{"id":"2479206780","title":"Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-Htn, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2479206780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479206780?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:00","pubTimestamp":1730289602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA3WFGKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2479067322","title":"Mineralys Therapeutics Inc - Topline Data From Launch-Htn Trial Expected Mid First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2479067322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479067322?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:00","pubTimestamp":1730289602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA3WFGKJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2477957336","title":"Mineralys Therapeutics to host KOL event on uncontrolled, resistant hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2477957336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477957336?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:26","pubTimestamp":1729600011,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (MLYS) announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-to-host-kol-event-on-uncontrolled-resistant-hypertension?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-to-host-kol-event-on-uncontrolled-resistant-hypertension?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLYS","LENZ","BK4139","KOL"],"gpt_icon":0},{"id":"2473779201","title":"Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2473779201","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473779201?lang=en_us&edition=fundamental","pubTime":"2024-10-07 19:52","pubTimestamp":1728301960,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/heres-why-were-not-too-worried-about-mineralys-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2095319765.USD","LU2210149790.SGD","BK4139","PSQ","NQmain","MNQmain",".IXIC","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","TQQQ","IE00BKPKM429.USD","LU2210150020.SGD","QLD","SQQQ","MLYS","BK4588","IE00BGHQF748.EUR","NDAQ","QID","BK4585"],"gpt_icon":1},{"id":"2470256536","title":"BRIEF-Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470256536?lang=en_us&edition=fundamental","pubTime":"2024-09-25 20:04","pubTimestamp":1727265892,"startTime":"0","endTime":"0","summary":"Sept 25  - Mineralys Therapeutics Inc   :   * MINERALYS THERAPEUTICS COMPLETES TARGET ENROLLMENT IN PIVOTAL ADVANCE-HTN TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION   * MINERALYS THERAPEUTICS INC - EXPECTS TO ANNOUNCE TOPLINE DATA IN Q1 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","LENZ","BK4139"],"gpt_icon":0},{"id":"2470478255","title":"Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2470478255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470478255?lang=en_us&edition=fundamental","pubTime":"2024-09-25 20:00","pubTimestamp":1727265601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240925:nTUA70LDGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2470255490","title":"Mineralys Therapeutics Inc - Expects to Announce Topline Data in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2470255490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470255490?lang=en_us&edition=fundamental","pubTime":"2024-09-25 20:00","pubTimestamp":1727265601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240925:nTUA70LDGM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2468339560","title":"Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2468339560","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468339560?lang=en_us&edition=fundamental","pubTime":"2024-09-18 01:27","pubTimestamp":1726594043,"startTime":"0","endTime":"0","summary":"Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs.Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful.Despite a solid cash position, further funding may be needed for regulatory stages, making acquisition by a major player a strategic move.Given its potential and current valuation, I recommend a cautious buy for Mineralys at these prices.   andreswd/E+ via Getty ImagesI covered Mineralys  in April last year. It had a few things going that got me interested: It was a new IPO, had just published positive phase 2 data, and it had a strong board of directors. The stock took a deep","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465572741/image_1465572741.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465572741/image_1465572741.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4721662-mineralys-in-hypertension-upcoming-catalysts-and-strong-positioning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","MLYS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com","stockEarnings":[{"period":"1week","weight":-0.0247},{"period":"1month","weight":-0.1491},{"period":"3month","weight":0.0224},{"period":"6month","weight":-0.027},{"period":"1year","weight":0.9916},{"period":"ytd","weight":0.3802}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction